Home / Journals / Journal of Endocrinology, Diabetes and Metabolic Complications / Articles In Press

Mini Review

Beyond the Numbers: A Comprehensive Approach to Cardiovascular Risk Assessment in Modern Healthcare

Authors: Bianchi D11 Giustina W11 Harrison F11 Yoneda P11 Giuliano H11 Menard S11

*Corresponding Author: Yoneda P, Department for Cardiovascular Diseases, Croatia

Copyright: © 2026 Yoneda P, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Yoneda P (2026). Beyond the Numbers: A Comprehensive Approach to Cardiovascular Risk Assessment in Modern Healthcare V1(3)

Received: Mar 06, 2026

Accepted: Mar 14, 2026

Published: Mar 24, 2026

Keywords: cardiovascular risk assessment, atherosclerosis, socioeconomic status, systemic inflammation, non-pharmacological interventions, precision medicine

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of global mortality, yet many events are preventable through early identification of risk. Cardiovascular risk assessment has evolved from simple measurements of blood pressure and cholesterol to multifactorial models incorporating genetic, behavioral, and environmental determinants. This article explores contemporary approaches to cardiovascular risk assessment, highlighting traditional risk factors, emerging biomarkers, and predictive tools. It also examines the integration of technology and personalized medicine in refining risk prediction. By emphasizing a proactive and individualized approach, this discussion underscores the critical role of early risk stratification in reducing disease burden and improving long-term outcomes.

Introduction

Cardiovascular risk assessment is a systematic process used to estimate an individual's likelihood of developing cardiovascular disease within a specific timeframe. It plays a central role in preventive medicine, enabling clinicians to implement early interventions and guide treatment strategies. As lifestyles change and non-communicable diseases rise, accurate and accessible risk assessment methods have become increasingly important.

Traditional Risk Factors

Historically, cardiovascular risk assessment has relied on well-established risk factors. These include:

  • Age and gender: Risk increases with age and is generally higher in males.

  • Hypertension: Elevated blood pressure damages blood vessels and accelerates atherosclerosis.

  • Hyperlipidemia: High levels of LDL cholesterol contribute to plaque formation.

  • Smoking: Tobacco use significantly increases the risk of heart disease and stroke.

  • Diabetes mellitus: Chronic hyperglycemia leads to vascular complications.

These factors form the foundation of most risk prediction models and remain critical in clinical evaluation.

Risk Assessment Tools and Models

Several validated tools are used worldwide to estimate cardiovascular risk:

  • Framingham Risk Score: Estimates 10-year risk based on age, cholesterol levels, blood pressure, and smoking status.

  • ASCVD Risk Calculator: Widely used to guide statin therapy decisions.

  • QRISK Score: Incorporates additional variables such as ethnicity and socioeconomic status.

While useful, these models may not fully capture individual variability, especially across diverse populations.

Emerging Risk Markers

Recent advancements have introduced additional markers that may enhance risk prediction:

  • High-sensitivity C-reactive protein (hs-CRP): Indicates systemic inflammation.

  • Coronary artery calcium (CAC) scoring: Detects calcified plaque in coronary arteries.

  • Genetic risk scores: Assess inherited susceptibility to cardiovascular disease.

  • Lipoprotein(a): An independent genetic risk factor linked to atherosclerosis.

These markers help refine risk estimation, particularly in borderline or intermediate-risk individuals.

Role of Lifestyle and Behavioral Factors

Lifestyle plays a crucial role in cardiovascular health. Poor diet, physical inactivity, stress, and inadequate sleep can significantly increase risk. Incorporating lifestyle assessment into risk evaluation provides a more holistic understanding and opens opportunities for non-pharmacological interventions.

Technological Advancements

Digital health technologies are transforming cardiovascular risk assessment:

  • Wearable devices: Track heart rate, activity levels, and sleep patterns.

  • Mobile health apps: Support self-monitoring and risk awareness.

  • Artificial intelligence (AI): Enhances predictive accuracy by analyzing large datasets and identifying complex patterns.

These innovations enable continuous monitoring and personalized risk profiling.

Challenges in Risk Assessment

Despite progress, several challenges persist:

  • Population variability: Risk models may not be equally accurate across different ethnic groups.

  • Data limitations: Incomplete or inaccurate patient data can affect predictions.

  • Over-reliance on algorithms: Clinical judgment remains essential in interpreting risk scores.

Addressing these issues requires ongoing research and model refinement.

Future Directions

The future of cardiovascular risk assessment lies in precision medicine. Integration of genomics, proteomics, and real-time health data will enable highly individualized risk predictions. Collaborative approaches combining clinical expertise with advanced analytics are expected to improve preventive strategies and patient outcomes.

Conclusion

Cardiovascular risk assessment is a dynamic and evolving field that plays a vital role in disease prevention. While traditional risk factors remain relevant, the incorporation of new biomarkers, advanced technologies, and personalized approaches is enhancing predictive accuracy. A comprehensive and patient-centered strategy is essential for effectively reducing the global burden of cardiovascular disease.

References

  1. Ruggenenti, P.; Iliev, I.; Costa, G.M.; Parvanova, A.; Perna, A.; Giuliano, G.A.; Motterlini, N.; Ene-Iordache, B.; Remuzzi, G. The BENEDICT Study Group. Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 2008, 31, 1629–1634.
  2. Levy, D.; Labib, S.B.; Anderson, K.M.; Christiansen, J.C.; Kannel, W.B.; Castelli, W.P. Determinants of Sensitivity and Specificity of Electrocardiographic Criteria for Left Ventricular Hypertrophy. Circulation 1990, 81, 815–820.
  3. Rider, O.J.; Ntusi, N.; Bull, S.C.; Nethononda, R.; Ferreira, V.; Holloway, C.J.; Holdsworth, D.; Mahmod, M.; Rayner, J.J.; Banerjee, R.; et al. Improvements in ECG Accuracy for Diagnosis of Left Ventricular Hypertrophy in Obesity. Heart 2016, 102, 1566–1572.
  4. Hashimoto, M.; Hossain, S.; Al Mamun, A.; Matsuzaki, K.; Arai, H. Docosahexaenoic Acid: One Molecule Diverse Functions. Crit. Rev. Biotechnol. 2017, 37, 579–597.
  5. Yordanova, V.; Staneva, G.; Angelova, M.; Vitkova, V.; Kostadinova, A.; Benkova, D.; Veleva, R.; Hazarosova, R. Modelling of Molecular Mechanisms of Membrane Domain Formation During the Oxidative Stress: Effect of Palmitoyloxovaleroyl-Phosphatidylcholine. Comptes Rendus L’acade’mie Bulg. Sci. 2021, 74, 78–87.
  6. Porthan, K.; Kenttä, T.; Niiranen, T.J.; Nieminen, M.S.; Oikarinen, L.; Viitasalo, M.; Hernesniemi, J.; Jula, A.M.; Salomaa, V.; Huikuri, H.V.; et al. ECG Left Ventricular Hypertrophy as a Risk Predictor of Sudden Cardiac Death. Int. J. Cardiol. 2019, 276, 125–129.
  7. Nistor, C.E.; Bugala, N.M.; Daguci, C.; Daguci, L.; Diaconu, O.A.; Rica, A.M. Multiple endocrine neoplasia type 2 syndrome and osteoporosis. Aging Clin. Exp. Res. 2023, 35, S387.
  8. Cameselle-García, S.; Abdulkader-Nallib, I.; Sánchez-Ares, M.; Cameselle-Teijeiro, J.M. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor. Oncol. Rep. 2024, 52, 119.